Despite hitting key goals across three late-stage studies, the drug, which targets the “OX40” ligand, raises safety and ...

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is ...

Friday, March 27, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Palantir ...

The Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...

Under the agreement, Kali Therapeutics is set to receive $180m in upfront and near-term payments.

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in ...

Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of ...

Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron ...